ArticleClinical immunology (Orlando, Fla.)2013
Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset.
Article in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial.Arthritis research & therapy · 2026Trial
- Stem Cell Therapy: A New Approach and Effective Treatment for Psoriasis.Dermatology practical & conceptual · 2025Review
- The myeloid switch: immune drivers in atopic dermatitis - roles in pathogenesis and emerging therapeutic targeting.Frontiers in immunology · 2025Review
- Exploring CCR5 + T regulatory cell subset dysfunction in type 1 diabetes patients: implications for immune regulation.Immunologic research · 2024Article
- Autoreactive T-Cells in Psoriasis: Are They Spoiled Tregs and Can Therapies Restore Their Functions?International journal of molecular sciences · 2023Review
- Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review.Clinical, cosmetic and investigational dermatology · 2023Review
- 3DFAACTS-SNP: using regulatory T cell-specific epigenomics data to uncover candidate mechanisms of type 1 diabetes (T1D) risk.Epigenetics & chromatin · 2022Article
- Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).Molecular immunology · 2022Article
- Ferroptosis: Mechanism and connections with cutaneous diseases.Frontiers in cell and developmental biology · 2022Review
- Potential Therapeutic Approaches through Modulating the Autophagy Process for Skin Barrier Dysfunction.International journal of molecular sciences · 2021Review
- Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.Frontiers in immunology · 2021Review
- Article
- [Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.Clinical reviews in allergy & immunology · 2020Review
- Advances in Understanding the Immunological Pathways in Psoriasis.International journal of molecular sciences · 2019Review
- Regulatory T cells in the treatment of disease.Nature reviews. Drug discovery · 2018Review
- The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis.Postepy dermatologii i alergologii · 2017Review
- The ratio of HLA-DR and VNN2Journal of neuro-oncology · 2017Article
- Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.Oncoimmunology · 2016Article
- Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.Mediators of inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
CCR5 expression on CD4(+)CD25(high)Foxp3(+) regulatory T cells (Tregs) has been reported to be crucial for limiting Th1 inflammation associated with autoimmunity and bacterial infections. We inquired whether abnormalities in chemokine receptors expressed on Tregs might be involved in the psoriatic pathogenesis. Indeed, the proportion of CCR5(+) Treg was 58.8% in healthy individuals (n=9), whereas only half as many CCR5(+) Treg cells were found in psoriatic individuals (29.1%, n=8, p<0.01). The flow-enriched control CCR5(+) Tregs consistently exceeded the suppressive capacity of unsorted Tregs in autologous MLR assays (n=5, p<0.05) showing that CCR5(+) Treg subset is a high potency regulatory T cell population. Interestingly, psoriatic CCR5(+) Treg cells exhibited significantly less migratory capacity toward CCR5 ligands MIP-1β and RANTES in vitro compared to CCR5(+) Treg controls (n=3, p<0.05). Our data demonstrate that psoriatic CCR5(+) Tregs cells are numerically-, functionally- and chemotactically-deficient compared to controls and may pose a triple impairment on the ability of psoriatic Tregs to restrain inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.